Wuhan YZY Biopharma Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 16, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	934	1,555	1,605	1,725	-	-
Market Cap Growth	8.31%	-3.14%	-6.97%	-	-	-
Enterprise Value	965	1,544	1,560	1,665	-	-
Last Close Price	4.82	8.02	8.28	8.90	-	-
PS Ratio	10.97	18.25	13.99	-	-	-
PB Ratio	-15.83	-26.34	49.40	12.27	-	-
P/TBV Ratio	-	-	49.40	12.27	-	-
EV/Sales Ratio	11.33	18.12	13.60	-	-	-
Debt / Equity Ratio	-2.41	-2.41	4.17	0.71	0.49	0.20
Net Debt / Equity Ratio	-0.52	-0.52	0.04	-0.83	-0.59	-0.40
Net Debt / EBITDA Ratio	-0.37	-0.37	-0.01	0.67	0.54	0.46
Net Debt / FCF Ratio	-	-	-0.01	0.57	0.52	0.57
Asset Turnover	0.35	0.35	0.38	-	0.01	-
Inventory Turnover	14.88	14.88	4.54	-	-	-
Quick Ratio	0.57	0.57	0.99	1.22	1.15	1.50
Current Ratio	0.66	0.66	1.19	1.44	1.63	2.21
Return on Equity (ROE)	-	-	-123.40%	-135.22%	-126.31%	-
Return on Assets (ROA)	-22.74%	-22.74%	-21.51%	-34.20%	-43.63%	-
Return on Capital Employed (ROCE)	315.60%	315.60%	-119.90%	-129.40%	-112.60%	-92.30%
Earnings Yield	-10.09%	-6.07%	-6.47%	-12.24%	-	-
FCF Yield	-	-	-6.78%	-12.00%	-	-
Buyback Yield / Dilution	-	-	-4.72%	-7.60%	-13.10%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.